The amylin analog that pairs with semaglutide for even greater appetite suppression and fat loss — the foundation of the "CagriSema" stack.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells; it slows gastric emptying, suppresses glucagon, and promotes satiety. Cagrilintide is engineered to last a full week per injection.
Its most well-known use is in combination with semaglutide — the CagriSema stack — which in Phase 2 trials produced body-weight loss greater than either drug alone. Phase 3 programs (REDEFINE) are ongoing, with FDA submission expected in 2026–2027.
Not yet FDA approved (Phase 3). Not WADA prohibited. Available as a research chemical only.
Binds amylin and calcitonin receptors in the hindbrain, slowing gastric emptying and producing post-meal satiety independent of GLP-1 pathways.
Because amylin works on different receptors than GLP-1, cagrilintide adds effect on top of semaglutide rather than competing for the same pathway. This is why the stack produces larger weight loss than either alone.
Reduces inappropriate post-meal glucagon release, supporting glycemic control without the hypoglycemia risk of insulin itself.
Most meaningful data comes from the CagriSema program. Cagrilintide monotherapy studies are smaller but support the mechanism.
| Benefit | Evidence |
|---|---|
| Weight loss (mono) | Phase 2: ~10% body-weight loss at 2.4 mg weekly over 26 weeks |
| Weight loss (stacked) | CagriSema Phase 2: ~17% body-weight loss over 32 weeks; REDEFINE trial ongoing |
| Appetite control | Significant reductions in food cravings and post-meal hunger |
| Glycemic control | Modest HbA1c reductions; complementary to GLP-1 agonists |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking Free| Weeks | Weekly Dose |
|---|---|
| 1–2 | 0.25 mg |
| 3–4 | 0.5 mg |
| 5–6 | 1.0 mg |
| 7–8 | 1.7 mg |
| 9+ | 2.4 mg (target) |
Hold at any step for an extra 2 weeks if GI side effects are pronounced. Some users stay at 1.7 mg if tolerability limits further escalation, though the Phase 2/3 trials (PMIDs 34798060, 40544433, 40544432) targeted 2.4 mg as the maintenance dose.
Most users pair cagrilintide with semaglutide at matched doses (e.g. both at 2.4 mg weekly). Inject on the same day but in different sites or (if pharma compounded) as a co-formulation.
0.25 mg weekly titrating to 2.4 mg over 8 weeks. Less total weight loss than CagriSema but fewer total side effects and lower cost.
10 mg vial + 2 mL BAC water = 5 mg/mL = 5000 mcg/mL
| Dose | Volume | Syringe Units |
|---|---|---|
| 0.25 mg | 0.05 mL | 5 units |
| 0.5 mg | 0.10 mL | 10 units |
| 1.0 mg | 0.20 mL | 20 units |
| 1.7 mg | 0.34 mL | 34 units |
| 2.4 mg | 0.48 mL | 48 units |
10 mg vial at 2.4 mg/week = ~4 weeks per vial
Use our free peptide calculator to figure out your reconstitution volume, draw amount, and syringe units.
Open Peptide CalculatorDosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Looking for Cagrilintide? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeDisclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.